Menopause Research Investment Trends and Funding Gaps

Menopause research funding is at a strange crossroads now. Private capital keeps pouring through the market faster than anyone thought plausible five years back, but the science base meant to underpin those businesses stays thin and fragile, structurally starved of cash. Untangling the two currents, with one accelerating and one just limping along, shows the field's path and what must shift before funding and medicine align.

Even the market's scale is contested, so begin there. Business Research Company says the 2025 menopause market is $18.78 billion, growing to a 2026 value of $19.95 billion at 6.2% compound growth, with $26.21 billion projected for 2030. Straits Research takes a different view: $19.26 billion for 2026, hitting $29.19 billion come 2034 at a 5.34% CAGR. SNS Insider focuses specifically on the treatment market, not the broader ecosystem, pegging it at $18.81 billion in 2025 and climbing to $31.95 billion by 2035. PwC's estimate is smaller, at $10 to 15 billion now and moving toward $15 to 25 billion in 2030, though people cited in Forbes say PwC's total is more a base rather than a cap, because it leaves out downstream spending from osteoporosis, cardiovascular disease, plus brain changes menopause accelerates.

The variance depends on what gets counted. Depends on the boundaries drawn: tight "treatment market" numbers add up one way, broad ecosystem figures another, and that framing shapes whether the field shows up as a small niche or a vast, underserved public health issue. SNS Insider says that by 2030, over 1.2 billion females globally will be menopausal or in postmenopausal stages, a population bigger than any one disease category tracked for health. In 2025, America accounted for the biggest portion at 38.40%, whereas Asia Pacific is expected to expand most quickly, with its 7.04% CAGR according to Straits Research. Whichever forecast someone trusts, the point stays the same: this fast-growing market is big, and likely bigger than any one figure captures.

Where private capital has been flowing and how funding habits have shifted

From 2020 to 2025, about $1.7 billion went into ventures tied to menopause, as funding rounds rose nearly 15% annually. VC makes up the bulk of transactions, over 80% of them, and it mostly backs tech-based care services like the apps and online clinics that link patients to providers. Big company deals, focused on pharma and consumer health, account for a portion of overall funding even though not many of them happen. They reflect two different bets across two different market levels: VC seeks scalable delivery infrastructure; pharma and consumer health seek tested offerings already earning money.

SVB's women's health numbers log $2 billion going into the space across 2025, yet domestic women's health VC specifically shed $1.2 billion over the same stretch. women's health VC specifically over that same period. First signs suggest a 2026 rebound, with a new cohort of Series A startups preparing to enter the market. At the same time, 25% of workplaces now provide dedicated support for menopause. Forbes says employers now offer dedicated benefits for menopause, rising from just 4% back in 2023. That rise points to more than consumer demand. Employers are treating menopause like a health problem that deserves budgeting.

A few 2025 transactions show where the funding is going. Pivotal Ventures teamed up with Wellcome Leap to put $100 million into women's health research. Through Pivotal, Melinda French Gates said $215 million would go to women's health as new philanthropic funding, naming menopause care and midlife support first, pushing her two-year commitment above $600 million. Midi Health, in menopause care, brought in a Series C of $50 million, with 500 providers now in all 50 states, moving toward unicorn. The Menopause Society kicked off a $10 million program aimed at growing the next wave of practitioners.

Startups in this space using AI are commanding valuations well beyond non-AI rivals, shaping where fresh capital concentrates. But almost all of this capital, philanthropic, VC, and corporate, is going toward commercial work and care delivery. The foundational science clinical practice actually relies on is not getting funding.

How much NIH spends on menopause research compared to everything else it funds

In FY2023, NIH set aside $56 million for menopause research, FY2024 brought $59 million, and FY2025 reached $78 million, as reported by MS Magazine's coverage of Congress's first menopause hearing. Against NIH's roughly $48 billion in funding, menopause research comes to a fraction small enough that it never appears among most summaries' line items.

This frames the situation more clearly. In that same FY2025, NIH reported $314 million for prostate cancer research alone, and $768 million across its broader "Men's Health Research" category, per Newsweek. Prostate cancer hits a large group of men. Menopause comes, sooner or later, for every woman who reaches it. Funding levels don't match population sizes, not loosely or otherwise.

Even with funding roughly doubling over two years, the field remains radically underfunded relative to its population impact. But a weak baseline moving modestly still leaves the field radically underfunded for its population impact. March 2024 saw the President launch an NIH-wide initiative addressing gaps in women's health research, with $200 million of NIH funding allocated from FY2025 to study perimenopause and menopause impacts on cardiovascular, neurological, and skeletal health, the National Network of Libraries of Medicine reports. That $200 million counts, but since the cash goes to women's health broadly and isn't earmarked just for menopause specifically, conflating those two overstates what's actually been promised.

A Nature editorial from January 2025 stated: "That something experienced by half of humanity is not more studied is little short of scandalous." The line doesn't need embellishment. The funding figures say the same thing in a different way.

The international funding picture and why it looks even thinner outside the domestic market

Away from the domestic market, funding gets even sparser. Nature reports Horizon Europe, the biggest multinational research-funding setup globally, gave a consortium a multimillion-euro grant, roughly equivalent in dollars, for Caramel, meant to stop cardiovascular disease in females 40 to 60. For menopause research specifically, it's a very big grant.

But Horizon Europe doesn't have a menopause category of its own, or one for women's health. Menopause research is folded into a broad "health" bucket, making it harder to pay for, harder to follow, and harder to push for, with no line item to show when asking for more. Nature's own reporting finds that few funders beyond NIH have matched its example by carving out dedicated space in the field, and the base looks thin by comparison.

At the grassroots end, the Menopause Society's Research Pilot Funding Program will back up to 3 new pilot efforts in 2026 at $50,000 each, with applications needed by September 21 and another funding round starting January 2027, an amount that pays for real early-stage work yet leaves this field reliant on small institutional grants rather than big ones. It’s not a trivial amount. It backs genuine early-stage research. Still, $50,000 for each study illustrates how heavily menopause research leans on small institutional grants instead of the funding cardiovascular disease and oncology research routinely draw. Caramel project's €12 million seems big compared with a pilot of $50,000, and marginal beside what cardiovascular research commands. Even when funding does come in, the field still runs short of money.

What WHI's funding cuts showed about how easily long menopause studies can fall apart

In 2025, the Women's Health Initiative came close to losing the Clinical Coordinating Center. By September 2025, centers and data collection were staring down a cutoff, with the CCC funded just up to January 2026, until HHS reversed that decision and confirmed funding as of April 25, 2025, per AJMC.

It's tough to overstate how much was in danger for a short time. The WHI has released over 2,400 peer-reviewed papers plus 342 ancillary reports, reflecting the work of 5,000+ investigators, placing it among the top longitudinal studies in women's health research. The hormone therapy study reshaped how doctors practice for decades, and its results are credited with keeping many people from getting breast cancer or cardiovascular disease. CCC closure would have done more than interrupt data collection. It would have put decades of built-up basic science that today's clinical care still leans on at risk.

The sequence carries a real sting. The FDA approved labeling changes in February 2026 removing references to cardiovascular disease from hormone-therapy treatments, concluding those warnings, rooted in data from WHI, had been used too broadly for too much time, per Newsweek. That very research, whose evidence drove those overly wide warnings, was heading toward defunding right as regulators were correcting how they applied its findings. This sequencing issue, correcting earlier evidence right when new evidence almost disappeared, gives the clearest illustration for why this field's longitudinal continuity is not optional. When research infrastructure this fragile breaks down, the evidence base regulators and clinicians depend on gets exposed in ways private capital can't patch.

The clinical evidence gaps that underfunding has left behind in practice

Women have long been left out of a substantial majority of clinical trials, says Portfolia, and that gap lands hardest in menopause research. Those going through premature menopause, with onset before 40, face a huge gap: the WHI mostly skipped them, so their health profiles and treatment choices still aren't well known now, says Reproductive Health in Frontiers.

The downstream results show in the time it takes before a woman receives care. Certainty News reports that getting a diagnosis for menopause can take years, which reflects decades of under-recognition instead of just trouble reaching care. PwC notes a large share of people with menopause never pursue treatment, a figure that works both ways: ongoing shame drives it, and so does a system that has offered little hope of real help on arrival.

A lot of it comes down to training. Under 30% of residents in training, and around a third of OB/GYNs in practice, get menopause training at all, per Forbes. Health plans usually pay for hormone therapy when prescribed, so the biggest thing blocking care comes from a training gap among people meant to prescribe. It's a training problem with the clinicians who are supposed to prescribe it. A handful of places are acting: Maryland, California, and New Jersey approved rules pushing their doctor panels to make menopause training mandatory for ongoing learning, MS Magazine reports.

Coverage gaps make the training gap worse. MS Magazine cited research showing just 26% of health plans pay for FDA-approved menopause care, while one in five patients skipped treatment or put it off over price. These issues don't stand alone. Undertrained doctors, patchy coverage, and a population conditioned to settle for less from health care compound one another, and the gap they leave is wider than any one training mandate or coverage mandate could fix alone.

What Congress's initial menopause session and proposed bills reveal about the current political landscape

September 2026 was a real milestone when Congress held menopause's first-ever dedicated hearing, picked up by Newsweek and MS Magazine. Two bills are moving forward with it. Newsweek reports that Lisa Murkowski and Patty Murray reintroduced the Advancing Menopause Care along with the Mid-Life Women's Health Act to authorize $275 million across five years for menopause as well as midlife health broadly, adding $25 million each year specifically toward NIH research, funding clinician training, community awareness efforts, and new Centers of Excellence focused on Mid-Life Women's Health. MS Magazine says the Veterans Menopause Research Act for Servicewomen would have the Departments of Defense and Veterans Affairs study research gaps for veterans and servicewomen.

With cross-party backing, the Murray-Murkowski proposal stands a better chance of advancing. Menopause has picked up bipartisan support in a Congress that rarely agrees on anything, which by itself gives the bill a better chance of actually moving. AHRQ also has a current Special Emphasis Notice soliciting research specifically into better care for menopause symptom treatment, running until December 20, 2027 per the Women's Health Office, showing U.S. bodies aim to steer researcher focus toward the field before new appropriations.

No funding has actually landed yet. Congressional bills authorize funding; they won't ensure it, and the gap between what's promised and what's actually appropriated tells its own significant tale here. Even so, doctors are getting on board too: from 2022 to 2024, applications for the Menopause Society's qualifying test went up five times, Nature says. Clinical momentum is building, though money still hasn't caught up to policy focus or clinical demand.

Where AI belongs in menopause care funding, and where it still falls short

Money is already flowing toward AI in menopause work, even though the clinical side hasn't caught up yet. Per SVB, in women's health, the commanding valuations AI-enabled startups get now top non-AI counterparts by a lot, making AI a straightforward valuation force, not just a bolt-on, in this market. The Flow Space reports that MIT's Female Medicine and Machine Learning program, launched to make AI for finding, spotting, plus delivery of women's health care, shows this trend moving past startups into research infrastructure as well.

But the clinical gap is striking. A study found that by 2025, zero menopause screening or care tools sat among 1,257 FDA-approved AI systems in medicine. Current machine learning work in this space is limited by clinical data that is sparse and inconsistently kept, and by databases underrepresenting Black, Latina, and Asian patients, so any AI model trained on that base could end up reproducing the very disparities the field wants to correct rather than actually fixing them.

The issue is circular. AI requires high-quality, organized clinical information to perform effectively. For decades, menopause research has gone without funding, so that data is missing at the scale and standard AI work needs. Underfunded research yields thin data, thin data makes AI that won't get validated, so the research gap turns into an AI gap and just extends that same shortfall to something new. All this while the wider health AI ecosystem speeds ahead without it: BioPharma Dive cited NVIDIA's 2026 poll showing 70% of medical and biology firms now run AI, up from 63% during 2025, plus 85% report bigger earnings already. Menopause care is not part of that trend now because the science it would draw from did not get the funding to make the data.